• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

散发性髓样甲状腺癌基因分型队列中分级的评估。

Evaluation of grade in a genotyped cohort of sporadic medullary thyroid carcinomas.

机构信息

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Division of Endocrinology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

出版信息

Histopathology. 2021 Sep;79(3):427-436. doi: 10.1111/his.14370. Epub 2021 Jun 15.

DOI:10.1111/his.14370
PMID:33763905
Abstract

AIMS

Tumour grade and RET mutation status, especially the presence of high-risk exon 15 and 16 RET mutations, have been reported to be prognostic in patients with sporadic medullary thyroid carcinoma (MTC). The aims of our study were to evaluate the performance of two recently proposed grading systems and to assess the association between grade and genotype in a cohort of sporadic MTCs.

METHODS AND RESULTS

We identified 44 sporadic MTCs. All available tumour slides were examined, and cases were assigned a grade on the basis of either mitotic count and tumour necrosis, or mitotic count, tumour necrosis, and Ki-67 proliferative index, as described in two recent studies. Additional clinicopathological features and outcome information were obtained from the pathology reports and electronic medical records. The presence of RET and RAS mutations was determined either with direct sequencing or with massively parallel sequencing. Both grading systems were prognostic for progression-free survival and disease-specific survival on univariate analysis. There was no correlation between grade and mutation status. Specifically, neither RET nor high-risk RET mutations were enriched in high-grade tumours, as assessed by either grading scheme.

CONCLUSION

Our findings suggest that grade is not correlated with RET/RAS mutation status, indicating that grade and genotype may give independent prognostic information.

摘要

目的

肿瘤分级和 RET 突变状态,特别是存在高风险的外显子 15 和 16 RET 突变,已被报道在散发性甲状腺髓样癌(MTC)患者中具有预后意义。我们的研究目的是评估两种最近提出的分级系统的性能,并在散发性 MTC 队列中评估分级与基因型之间的关联。

方法和结果

我们确定了 44 例散发性 MTC。根据最近两项研究中描述的有丝分裂计数和肿瘤坏死或有丝分裂计数、肿瘤坏死和 Ki-67 增殖指数,对所有可用的肿瘤切片进行了检查,并对病例进行了分级。从病理报告和电子病历中获得了其他临床病理特征和结局信息。通过直接测序或大规模平行测序确定了 RET 和 RAS 突变的存在。两种分级系统在单因素分析中均对无进展生存期和疾病特异性生存期具有预后意义。分级与突变状态之间没有相关性。具体来说,两种分级方案均未显示高分级肿瘤中富集 RET 或高风险 RET 突变。

结论

我们的发现表明,分级与 RET/RAS 突变状态无关,表明分级和基因型可能提供独立的预后信息。

相似文献

1
Evaluation of grade in a genotyped cohort of sporadic medullary thyroid carcinomas.散发性髓样甲状腺癌基因分型队列中分级的评估。
Histopathology. 2021 Sep;79(3):427-436. doi: 10.1111/his.14370. Epub 2021 Jun 15.
2
International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.国际甲状腺髓样癌分级系统:甲状腺髓样癌的有效分级系统。
J Clin Oncol. 2022 Jan 1;40(1):96-104. doi: 10.1200/JCO.21.01329. Epub 2021 Nov 3.
3
A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis.基于增殖活性(Ki-67 和有丝分裂计数)和凝固性坏死的甲状腺髓样癌分级方案建议
Am J Surg Pathol. 2020 Oct;44(10):1419-1428. doi: 10.1097/PAS.0000000000001505.
4
Novel RET mutations in macedonian patients with medullary thyroid carcinoma: genotype-phenotype correlations.马其顿甲状腺髓样癌患者中的新型RET突变:基因型与表型的相关性
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(1):93-107.
5
Grading of Medullary Thyroid Carcinoma: an Interobserver Reproducibility Study.甲状腺髓样癌分级:一项观察者间可重复性研究。
Endocr Pathol. 2022 Sep;33(3):371-377. doi: 10.1007/s12022-022-09718-0. Epub 2022 May 13.
6
Independent Validation of the International Grading System for Medullary Thyroid Carcinoma: A Single Institution Experience.孤立性髓样甲状腺癌国际分级系统的独立验证:单中心经验。
Mod Pathol. 2023 Sep;36(9):100235. doi: 10.1016/j.modpat.2023.100235. Epub 2023 Jun 1.
7
Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease.髓样甲状腺癌:散发性疾病检测中生存分析及突变特异性免疫组化评估
World J Surg. 2018 May;42(5):1432-1439. doi: 10.1007/s00268-018-4551-8.
8
Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma.对 66 例甲状腺髓样癌患者的分子数据与组织病理学和临床特征的相关性分析。
J Endocrinol Invest. 2021 Sep;44(9):1837-1846. doi: 10.1007/s40618-020-01456-6. Epub 2021 Feb 11.
9
Grading medullary thyroid carcinoma on fine-needle aspiration cytology specimens with the International Medullary Thyroid Carcinoma Grading System: A cytologic-histologic correlation.用国际甲状腺髓样癌分级系统对细针抽吸细胞学标本进行甲状腺髓样癌分级:细胞学-组织学相关性。
Cancer Cytopathol. 2024 Apr;132(4):224-232. doi: 10.1002/cncy.22778. Epub 2023 Dec 8.
10
Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.C 细胞神经内分泌肿瘤更新:甲状腺髓样癌的预后和预测的组织病理学和分子特征。
Endocr Pathol. 2023 Mar;34(1):1-22. doi: 10.1007/s12022-023-09753-5. Epub 2023 Mar 8.

引用本文的文献

1
Histopathology of C Cells and Medullary Thyroid Carcinoma.C细胞与甲状腺髓样癌的组织病理学
Recent Results Cancer Res. 2025;223:9-50. doi: 10.1007/978-3-031-80396-3_2.
2
Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study.国际多中心研究中髓样甲状腺癌基因组图谱与肿瘤特征和临床结局的关联。
Thyroid. 2024 Feb;34(2):167-176. doi: 10.1089/thy.2023.0279. Epub 2023 Nov 7.
3
Independent Validation of the International Grading System for Medullary Thyroid Carcinoma: A Single Institution Experience.
孤立性髓样甲状腺癌国际分级系统的独立验证:单中心经验。
Mod Pathol. 2023 Sep;36(9):100235. doi: 10.1016/j.modpat.2023.100235. Epub 2023 Jun 1.
4
Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.C 细胞神经内分泌肿瘤更新:甲状腺髓样癌的预后和预测的组织病理学和分子特征。
Endocr Pathol. 2023 Mar;34(1):1-22. doi: 10.1007/s12022-023-09753-5. Epub 2023 Mar 8.
5
External Validation of Three Available Grading Systems for Medullary Thyroid Carcinoma in a Single Institution Cohort.单一机构队列中三种髓样甲状腺癌分级系统的外部验证。
Endocr Pathol. 2022 Sep;33(3):359-370. doi: 10.1007/s12022-022-09719-z. Epub 2022 May 18.
6
Overview of the 2022 WHO Classification of Thyroid Neoplasms.2022 年世卫组织甲状腺肿瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14.
7
International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.国际甲状腺髓样癌分级系统:甲状腺髓样癌的有效分级系统。
J Clin Oncol. 2022 Jan 1;40(1):96-104. doi: 10.1200/JCO.21.01329. Epub 2021 Nov 3.